- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
20/20 Biolabs and Applied DNA Sciences Compete in Biotech Services
Two small-cap biotech firms vie for market share in diagnostics and drug development.
Mar. 28, 2026 at 6:43am
Got story updates? Submit your updates here. ›
Applied DNA Sciences (NASDAQ:BNBX) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap biotech services companies, but which one is the stronger business? The companies differ in their product offerings, revenue, and profitability, with 20/20 Biolabs reporting higher earnings despite lower overall revenue compared to Applied DNA Sciences.
Why it matters
The competition between these two firms highlights the dynamic nature of the biotech services industry, where companies must continually innovate and differentiate their offerings to attract customers and investors. The performance of these companies is also a barometer for the broader trends in the biotech sector, which has seen significant growth and investment in recent years.
The details
Applied DNA Sciences develops and markets DNA-based technology solutions for diagnostics, drug development, and supply chain security. In contrast, 20/20 Biolabs focuses on AI-powered blood tests for early cancer and disease detection. Both companies operate clinical laboratories and provide contract research services, but have different product mixes and revenue streams.
- Applied DNA Sciences was formerly known as Datalink Systems, Inc. and changed its name in 2002.
- 20/20 Biolabs wound down its COVID-19 testing business to focus on its OneTest cancer and longevity product lines.
- 20/20 Biolabs expects to launch its OneTest for Longevity product in the first half of 2026.
The players
Applied DNA Sciences, Inc.
A biotech company that develops and markets DNA-based technology solutions for diagnostics, drug development, and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name in 2002. It is headquartered in Stony Brook, New York.
20/20 Biolabs
A biotech company that develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company's principal executive offices are located in Gaithersburg, Maryland.
What’s next
20/20 Biolabs expects to launch its OneTest for Longevity product in the first half of 2026, which will expand the company's portfolio of AI-powered diagnostic tests.
The takeaway
The competition between Applied DNA Sciences and 20/20 Biolabs highlights the ongoing innovation and differentiation within the biotech services industry, as companies strive to develop new technologies and products to meet the growing demand for early disease detection and prevention.
